Guardant Health, Inc.
GHHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGuardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company carries a $21.60B market cap, placing it firmly in the large-cap category. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Market Cap
$21.60B
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
-363.92
EPS (TTM)
$-3.50
EPS (Fwd)
$-0.44
ROE
—
ROA
-18.1%
Cash
$1.05B
Total Debt
$1.70B
Free CF
$26.6M
52W Change
185.3%
Annual Financials
Cash vs Debt
Where GH stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, GH finished 36.85% above its 150-day moving average ($120.14) and 41.27% above its 200-day moving average ($116.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GH overbought or oversold?
At the September 2, 2026 close, GH's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.05B in cash, though total debt stands at $1.70B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $26.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Revenue has grown from $449.5M (2022) to $982.0M (2025), reflecting a 118% increase over the period.
Guardant Health, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GH.